[go: up one dir, main page]

AU2002218006A1 - Compositions and methods for the diagnosis of cancer - Google Patents

Compositions and methods for the diagnosis of cancer

Info

Publication number
AU2002218006A1
AU2002218006A1 AU2002218006A AU1800602A AU2002218006A1 AU 2002218006 A1 AU2002218006 A1 AU 2002218006A1 AU 2002218006 A AU2002218006 A AU 2002218006A AU 1800602 A AU1800602 A AU 1800602A AU 2002218006 A1 AU2002218006 A1 AU 2002218006A1
Authority
AU
Australia
Prior art keywords
fancd2
sequence
gene
cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002218006A
Other languages
English (en)
Inventor
Alan D. D'andrea
Markus Grompe
Toshiyasu Taniguchi
Cynthia Timmers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Oregon Health and Science University
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of AU2002218006A1 publication Critical patent/AU2002218006A1/en
Priority to AU2008201172A priority Critical patent/AU2008201172B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • G01N33/5758
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G01N33/575
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/075Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
AU2002218006A 2000-11-03 2001-11-02 Compositions and methods for the diagnosis of cancer Abandoned AU2002218006A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2008201172A AU2008201172B2 (en) 2000-11-03 2008-03-12 Methods and Compositions for the Diagnosis of Cancer Susceptibilites and Defective DNA Repair Mechanisms and Treatment Thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24575600P 2000-11-03 2000-11-03
US60/245,756 2000-11-03
PCT/US2001/045561 WO2002036761A2 (fr) 2000-11-03 2001-11-02 Procedes et compositions pour le diagnostic des sensibilites aux cancers et mecanismes de reparation d'adn defectueux et traitement correspondant

Publications (1)

Publication Number Publication Date
AU2002218006A1 true AU2002218006A1 (en) 2002-05-15

Family

ID=22927953

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002218006A Abandoned AU2002218006A1 (en) 2000-11-03 2001-11-02 Compositions and methods for the diagnosis of cancer

Country Status (6)

Country Link
US (1) US20030093819A1 (fr)
EP (2) EP1349924A2 (fr)
JP (2) JP2004536555A (fr)
AU (1) AU2002218006A1 (fr)
CA (1) CA2427802A1 (fr)
WO (1) WO2002036761A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030188326A1 (en) 2000-11-03 2003-10-02 Dana Farber Cancer Institute Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
US7858331B2 (en) * 2000-11-03 2010-12-28 Dana Farber Cancer Institute, Inc. Compositions and methods for the treatment of cancer
CA2465949A1 (fr) 2001-11-02 2003-05-15 Dana-Farber Cancer Institute Procedes et compositions de diagnostic des sensibilites au cancer, mecanismes de reparation d'adn defectueux et traitement correspondant
US7927840B2 (en) 2006-09-11 2011-04-19 Gen Probe Incorporated Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region
AU2003298605B2 (en) * 2002-10-16 2007-10-18 Gen-Probe Incorporated Compositions and methods for detecting west nile virus
US20050009110A1 (en) * 2003-07-08 2005-01-13 Xiao-Jia Chang Methods of producing antibodies for diagnostics and therapeutics
US8227434B1 (en) 2003-11-04 2012-07-24 H. Lee Moffitt Cancer Center & Research Institute, Inc. Materials and methods for treating oncological disorders
JP2007521811A (ja) 2004-01-30 2007-08-09 ダナ ファーバー キャンサー インスティテュート 放射線又は遺伝毒性物質曝露の測定及び定量方法
EP1904088A4 (fr) * 2005-05-24 2010-03-31 Dana Farber Cancer Inst Inc Compositions et methodes de traitement du cancer
CA2670913A1 (fr) 2005-12-06 2007-06-14 Oregon Health & Science University Essai de criblage acellulaire et procedes d'utilisation
US20090305266A1 (en) * 2006-05-03 2009-12-10 Bagby Grover C Test for ovarian cancer by detecting abnormality in fancd2 pathway
US8583380B2 (en) 2008-09-05 2013-11-12 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
WO2011160206A1 (fr) 2010-06-23 2011-12-29 Morin Ryan D Biomarqueurs pour lymphomes non hodgkiniens et leurs utilisations
US20130195843A1 (en) * 2010-06-23 2013-08-01 British Columbia Cancer Agency Branch Biomarkers for Non-Hodgkin Lymphomas and Uses Thereof
US9309556B2 (en) 2010-09-24 2016-04-12 The Board Of Trustees Of The Leland Stanford Junior University Direct capture, amplification and sequencing of target DNA using immobilized primers
MA45408A (fr) 2016-06-17 2019-04-24 Magenta Therapeutics Inc Compositions et procédés pour la déplétion des cellules cd117+
KR20240161216A (ko) 2017-01-20 2024-11-12 하이델베르크 파마 리서치 게엠베하 Cd137+ 세포의 고갈을 위한 조성물 및 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048729A (en) 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
US6280935B1 (en) 1994-10-13 2001-08-28 Lynx Therapeutics, Inc. Method of detecting the presence or absence of a plurality of target sequences using oligonucleotide tags
DE69636068T2 (de) 1995-02-21 2006-11-30 Cantab Pharmaceuticals Research Ltd. Virale zubereitungen, vektoren, immunogene und impfstoffe
GB9507238D0 (en) 1995-04-07 1995-05-31 Isis Innovation Detecting dna sequence variations
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
NZ326525A (en) 1995-12-18 1999-11-29 Endorecherche Inc Chromosome 13-linked breast cancer susceptibility gene
US6297010B1 (en) 1998-01-30 2001-10-02 Genzyme Corporation Method for detecting and identifying mutations
US6287772B1 (en) 1998-04-29 2001-09-11 Boston Probes, Inc. Methods, kits and compositions for detecting and quantitating target sequences

Also Published As

Publication number Publication date
EP2298878A3 (fr) 2011-11-16
EP1349924A2 (fr) 2003-10-08
US20030093819A1 (en) 2003-05-15
WO2002036761A3 (fr) 2003-07-03
EP2298878A2 (fr) 2011-03-23
JP2010246550A (ja) 2010-11-04
CA2427802A1 (fr) 2002-05-10
WO2002036761A9 (fr) 2002-08-01
JP2004536555A (ja) 2004-12-09
WO2002036761A2 (fr) 2002-05-10

Similar Documents

Publication Publication Date Title
RU2161309C2 (ru) Мутации гена мтs в зародышевой линии и способ выявления предрасположенности к злокачественным опухолям в гене мтs
KR100599454B1 (ko) 종양 억제자로 작용하는 aim3의 신규 용도
JP2010246550A (ja) 癌感受性の診断のための方法及び組成物並びに欠損dna修復メカニズム及びその処置
US9354224B2 (en) Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
AU707636C (en) Materials and methods relating to the identification and sequencing of the BRCA2 cancer susceptibility gene and uses thereof
CA2539837C (fr) Identification d'antigenes de surface cellulaire associes a une tumeur dans le cadre d'un diagnostic et d'une therapie
ES2537319T3 (es) Identificación de antígenos asociados a superficies para el diagnóstico y la terapia de tumores
EP0826031B1 (fr) Gene de l'ataxia-telangiectasie et son organisation genomique
EP0440744A1 (fr) Produits et procedes de regulation de la suppression du phenotype neoplastique
JPH08510651A (ja) Mts遺伝子、それにおける変異、およびmts遺伝子配列を用いる癌の診断方法
RU2164419C2 (ru) Ген mts, мутации данного гена и способы диагностики злокачественных опухолей с использованием последовательности гена mts
US7052889B2 (en) Mammalian SUV39H2 proteins and isolated DNA molecules encoding them
JP2005520543A (ja) 癌における新規組成物および方法
EP1451343B1 (fr) Procedes et compositions de diagnostic des sensibilites au cancer, mecanismes de reparation d'adn defectueux et traitement correspondant
AU2008201172B2 (en) Methods and Compositions for the Diagnosis of Cancer Susceptibilites and Defective DNA Repair Mechanisms and Treatment Thereof
JP2009039100A (ja) 癌感受性および欠陥のあるdna修復機構の診断方法および組成物、ならびにそれらを治療するための方法および組成物
WO2001055450A2 (fr) GENES AMPLIFIES EN 17q23
WO2002020848A2 (fr) Gene et variation de sequence associes au cancer
US20060041111A1 (en) Dock 3 tumor suppressor gene
US20050089858A1 (en) Salvador tumor suppressor gene
WO2003062398A2 (fr) Nouveau gene suppresseur de tumeur, la p28ing5
Liang United States Patent te
Iles The Cell
Eva et al. 2. Role of the retinoblastoma gene in the oncogenesis
EP2618147A1 (fr) Réactif pour tester des tumeurs et composition pharmaceutique pour la prévention tumorale

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted